Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.

European journal of gastroenterology & hepatology·2026
Same author

Adherence to 2020 US Multi-Society Task Force Guidelines for Post-Polypectomy Surveillance: a Multicenter Real-Time Analysis.

Journal of gastrointestinal cancer·2026
Same author

Laparoscopic liver biopsy for safe tissue acquisition in suspected PSVD or NCPF.

Journal of hepatology·2026
Same author

The impact of COVID-19 on alcohol-associated hepatitis and alcohol-associated cirrhosis.

The American journal of the medical sciences·2026
Same author

Caregiver Involvement and Burden and Patient Quality of Life in Patients With Decompensated Cirrhosis.

The American journal of gastroenterology·2026

Related Experiment Video

Updated: May 14, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

End-stage liver disease complications.

Robert S Rahimi1, Don C Rockey

  • 1Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas, USA.

Current Opinion in Gastroenterology
|February 23, 2013
PubMed
Summary

New strategies improve outcomes for chronic liver disease patients. Advances in managing complications like hepatic encephalopathy and ascites offer better patient care and reduced hospital readmissions.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure
07:29

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure

Published on: August 14, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure
07:29

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure

Published on: August 14, 2017

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Chronic liver disease leads to serious complications such as hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemorrhage (EVH).
  • Effective management of these conditions is crucial for improving patient morbidity and mortality rates.

Purpose of the Study:

  • To review recent advancements in the clinical management of cirrhosis and its associated complications.
  • To highlight novel therapeutic strategies and their impact on patient outcomes.

Main Methods:

  • Literature review of recent studies on the management of liver disease complications.
  • Analysis of treatment efficacy, cost-effectiveness, and patient outcomes for various therapies.

Main Results:

  • Predictors for minimal hepatic encephalopathy (MHE) treatment response identified; rifaximin showed marginal benefits over lactulose but was less cost-effective.
  • Nonselective beta-blockers may reduce ascites and HRS development in responders.
  • Noradrenaline is a cost-effective alternative to terlipressin for type 1 HRS.
  • Hemorrhagic ascites indicates a poor prognosis.
  • Intravenous proton pump inhibitors offer an alternative to vasoconstrictors for acute EVH with fewer side effects.

Conclusions:

  • Continuous refinement of clinical management strategies for cirrhosis complications is essential.
  • These advancements contribute to improved patient outcomes and quality of life.